COMPOUNDS FOR TREATMENT OR PREVENTION OF DISORDERS OF NERVOUS SYSTEM AND SYMPTOMS AND MANIFESTATIONS THEREOF, AND FOR CYTO-PROTECTION AGAINST DISEASES AND AGING OF CELLS, AND SYMPTOMS AND MANIFESTATIONS THEREOF

To provide safe and effective compounds, compositions, drugs, and methods for treating and/or preventing neurological system disorders and/or their neurological symptoms and manifestations, for improving cognitive functions, or for treating and preventing endocrine-metabolic system disorders, hyper...

Full description

Saved in:
Bibliographic Details
Main Authors CHARLES E INTURRISI, PAOLO L MANFREDI
Format Patent
LanguageEnglish
Japanese
Published 12.03.2024
Subjects
Online AccessGet full text

Cover

More Information
Summary:To provide safe and effective compounds, compositions, drugs, and methods for treating and/or preventing neurological system disorders and/or their neurological symptoms and manifestations, for improving cognitive functions, or for treating and preventing endocrine-metabolic system disorders, hyper blood pressure, ischemic heart diseases, age-related disorders, or eye or skin diseases.SOLUTION: Disclosed is a pharmaceutical composition comprising a substance selected from d-methadone, β-d-methadol, α-d-methadol, α-d-acetylmethadol, β-d-acetylmethadol, α-d-normethadol and pharmaceutically acceptable salts and mixtures thereof, which is administered to a subject under conditions effective for the substance to: (a) modulate levels of brain derived neurotrophic factor (BDNF) or testosterone in the subject; (b) bind to NMDA receptor, NET or SERT of the subject; or (c) modulate cellular K+, Ca2++, or Na+ current of the subject.SELECTED DRAWING: Figure 1 【課題】神経系障害、神経系障害の症状及び徴候を処置若しくは予防するため、又は認知機能を改善するため、又は内分泌代謝障害、若しくは高血圧、若しくは虚血性心疾患、若しくは加齢性障害、若しくは眼疾患、若しくは皮膚疾患を処置若しくは予防するための安全で有効な化合物、組成物、薬物、及び方法を提供すること。【解決手段】(a)対象内の脳由来神経栄養因子(BDNF)若しくはテストステロンのレベルを調節する、(b)対象のNMDA受容体、NET、又はSERTに結合する、又は(c)対象の細胞のK+、Ca2++、又はNa+電流を調節するのに有効な条件下で投与される、d-メサドン、β-d-メタドール、α-d-メタドール、α-d-アセチルメタドール、β-d-アセチルメタドール、α-d-ノルメタドール、それらの薬学的に許容可能な塩、及びそれらの混合物から選択される物質を含む医薬組成物により、上記課題を解決する。【選択図】図1
Bibliography:Application Number: JP20240002598